Covid 19 Research using Clinical Trials (Home Page)
Report for D003095: Collagen Diseases NIH
(Synonyms: Collagen Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug479 | COVID-19 patients Wiki | 0.50 |
| drug477 | COVID-19 infection Wiki | 0.50 |
| drug470 | COVID-19 barrier box Wiki | 0.50 |
| drug883 | Exercise brochure Wiki | 0.50 |
| drug2977 | questionnaire assesment Wiki | 0.45 |
| drug2465 | Telerehabilitation Wiki | 0.25 |
| drug560 | Chloroquine Wiki | 0.18 |
| drug1853 | Placebo oral tablet Wiki | 0.09 |
Correlated MeSH Terms (11)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012216 | Rheumatic Diseases NIH | 0.89 |
| D012213 | Rheumatic Fever NIH | 0.71 |
| D001167 | Arteritis NIH | 0.35 |
| D001168 | Arthritis NIH | 0.29 |
| D001327 | Autoimmune Diseases NIH | 0.29 |
| D011111 | Polymyalgia Rheumatica NIH | 0.29 |
| D013700 | Giant Cell Arteritis NIH | 0.29 |
| D015535 | Arthritis, Psoriatic NIH | 0.25 |
| D059350 | Chronic Pain NIH | 0.20 |
| D008180 | Lupus Erythematosus, Systemic NIH | 0.20 |
| D001172 | Arthritis, Rheumatoid NIH | 0.19 |
Correlated HPO Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012089 | Arteritis HPO | 0.35 |
| HP:0002960 | Autoimmunity HPO | 0.29 |
| HP:0001369 | Arthritis HPO | 0.29 |
| HP:0012532 | Chronic pain HPO | 0.20 |
| HP:0002725 | Systemic lupus erythematosus HPO | 0.20 |
| HP:0001370 | Rheumatoid arthritis HPO | 0.19 |
There are 4 clinical trials
Clinical Trials
1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases
The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.
NCT04335747 Rheumatoid Arthritis Psoriatic Arthritis Axial Spondyloarthritis Systemic Lupus Erythematosus Giant Cell Arteritis Other: COVID-19 infection MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus
Primary Outcomes
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusion
Secondary Outcomes
Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusion
Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1
2 Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak
Primary Outcomes
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusionSecondary Outcomes
Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusionDescription: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration. In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression. During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients. The present study is an "emergency" being realize before the end of the quarantine.
NCT04351399 Sars-CoV2 Rheumatic Diseases Rheumatoid Arthritis Chronic Pain Other: questionnaire assesment MeSH:Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain
HPO:Arthritis Chronic pain Polyarticular arthritis Rheumatoid arthritis
Primary Outcomes
Measure: Frequency of RA patients with emotional impact (feeling of isolation) Time: maximum 1 week from baseline on
Secondary Outcomes
Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.
Measure: self-reported questionnaire for painful Time: maximum 1 week from baseline on
3 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study
Primary Outcomes
Measure: Frequency of RA patients with emotional impact (feeling of isolation) Time: maximum 1 week from baseline onSecondary Outcomes
Description: Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.
Measure: self-reported questionnaire for painful Time: maximum 1 week from baseline onSince December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.
NCT04353609 Sars-CoV2 Chronic Inflammatory Rheumatism Autoimmune Diseases MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
HPO:Autoimmunity
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19
Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19
Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
4 Morbimortality of Covid-19 in Patients With Chronic Inflammatory Rheumatism Treated With Immunosuppressants
Primary Outcomes
Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death Time: From Baseline up to Day 21 after first symptoms of covid-19Secondary Outcomes
Measure: Proportion of patients who die from a severe form of covid-19 Time: From Baseline up to Day 21 after first symptoms of covid-19Measure: Proportion of patients who present an history of diabetes according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2) Time: At the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Asthma according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Hypertension according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cardiac disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of stroke according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
Measure: Proportion of patients who present an history of cancer according to medical records Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
A retrospective monocentric study with large active files of patients monitored for rheumatoid arthritis, spondyloarthritis and systemic lupus erythematosus with as main endpoint the morbimortality of Covid-19 in these patients (number of patients hospitalized in conventional units and/or in intensive care and/or deceased). The results will be compared with those of the general population based on the epidemiological data of Covid-19.
NCT04426279 Sars-CoV2 Rheumatoid Arthritis Rheumatic Diseases Other: questionnaire assesment MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases
Primary Outcomes
Description: The diagnosis of Covid-19 is either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. The results will be compared with those of the general population based on Covid-19 epidemiological data.
Measure: the number of patients with severe Covid-19 who were admitted to a conventional unit and/or an ICU and/or deceased, during the Covid-19 epidemic wave (from March to August 2020) among patients with IRC under IS. Time: At 6 monthsSecondary Outcomes
Measure: Diagnosis of Covid-19 either confirmed by diagnostic test (RT-PCR), or by a physician, or by serology. Time: At 6 monthsMeasure: The number of patients admitted to conventional unit and/or ICU and/or deceased among patients with IRC under IS between the Covid-19 epidemic wave (March to August 2020) and the six-month period preceding it (September to February 2020). Time: At 6 months
Description: Treatment modification will be assessed by the number of weeks of treatment not taken, the number of injections not given, the number of delayed or missed infusions. Among those who have modified or stopped their treatment, the impact on their diseases will be evaluated by the loss of remission, the patient's opinion on the notion of relapse, the increase or initiation of corticosteroid therapy and the substantive change in treatment.
Measure: The number of patients who maintained, modified, or discontinued their treatment. Time: At 6 months